<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971357</url>
  </required_header>
  <id_info>
    <org_study_id>2018-009</org_study_id>
    <nct_id>NCT03971357</nct_id>
  </id_info>
  <brief_title>Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration</brief_title>
  <official_title>Prospective Randomized Study to Determine Whether Use of Rhopressa™ Accelerates Corneal Clearing After Removal of Descemet Membrane for Treatment of Fuchs Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Price Vision Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Price Vision Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with Fuchs dystrophy will be randomized to use either netarsudil or placebo eye
      drops to determine if the use of netarsudil accelerates migration of host peripheral corneal
      endothelial cells to restore the central endothelial cell layer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects with Fuchs endothelial dystrophy will have the central corneal endothelium and
      guttae-covered Descemet membrane surgically removed. Subjects will be randomized to use
      netarsudil or placebo eye drops once daily. Visual acuity, corneal clearing and central
      endothelial cell density will be monitored for the 3-month study duration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of corneal clearing after endothelial removal for treatment of Fuchs dystrophy</measure>
    <time_frame>6 weeks</time_frame>
    <description>Area of cornea that has not cleared as a proportion of the area stripped of endothelium</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to complete corneal clearing</measure>
    <time_frame>3 months</time_frame>
    <description>Number of days from endothelial removal to complete corneal clearing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central endothelial cell density</measure>
    <time_frame>3 months</time_frame>
    <description>Central corneal endothelial cell density assessed with specular microscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach corrected distance visual acuity of 20/40 or better</measure>
    <time_frame>3 months</time_frame>
    <description>Number of days from endothelial removal to recovery of corrected distance visual acuity of 20/40 or better</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Fuchs' Endothelial Dystrophy</condition>
  <arm_group>
    <arm_group_label>Netarsudil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Netarsudil ophthalmic solution 0.02%, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo eye drop, dosed topically daily for the 3-month study duration or until 2 weeks after corneal clearing is complete, whichever occurs sooner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netarsudil</intervention_name>
    <description>netarsudil opthalmic solution 0.02%</description>
    <arm_group_label>Netarsudil</arm_group_label>
    <other_name>Rhopressa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo eye drops</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patient at least 18 years of age and of any race or ethnicity who is
             undergoing Descemet stripping only for Fuchs dystrophy

          -  Is able and willing to administer eye drops

          -  Is able to comprehend and has signed the Informed Consent form.

        Exclusion Criteria:

          -  Active intraocular inflammation

          -  Corneal ulceration, keratitis, or conjunctivitis

          -  Known sensitivity to any of the ingredients in the study medications

          -  Abnormal eyelid function

          -  History of herpetic keratitis

          -  History of non-compliance with using prescribed medication

          -  Current or planned pregnancy within the study duration

          -  Concurrent involvement or participation in another randomized clinical trial within 30
             days prior to enrollment in this study

          -  Any ocular or systemic condition (i.e., UNCONTROLLED systemic disease) or situation
             which in the investigator's opinion may put the patient at significant risk, confound
             the study results, or interfere significantly with the patient's participation in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis W Price, Jr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Price Vision Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianne O Price, PhD</last_name>
    <phone>317-814-2990</phone>
    <email>mprice@cornea.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis W Price, Jr., MD</last_name>
    </contact>
    <investigator>
      <last_name>Francis W Price, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Arbelaez JG, Price MO, Price FW Jr. Long-term follow-up and complications of stripping descemet membrane without placement of graft in eyes with Fuchs endothelial dystrophy. Cornea. 2014 Dec;33(12):1295-9. doi: 10.1097/ICO.0000000000000270.</citation>
    <PMID>25299425</PMID>
  </reference>
  <reference>
    <citation>Moloney G, Petsoglou C, Ball M, Kerdraon Y, Höllhumer R, Spiteri N, Beheregaray S, Hampson J, DʼSouza M, Devasahayam RN. Descemetorhexis Without Grafting for Fuchs Endothelial Dystrophy-Supplementation With Topical Ripasudil. Cornea. 2017 Jun;36(6):642-648. doi: 10.1097/ICO.0000000000001209.</citation>
    <PMID>28476048</PMID>
  </reference>
  <reference>
    <citation>Borkar DS, Veldman P, Colby KA. Treatment of Fuchs Endothelial Dystrophy by Descemet Stripping Without Endothelial Keratoplasty. Cornea. 2016 Oct;35(10):1267-73. doi: 10.1097/ICO.0000000000000915.</citation>
    <PMID>27310885</PMID>
  </reference>
  <reference>
    <citation>Soh YQ, Mehta JS. Regenerative Therapy for Fuchs Endothelial Corneal Dystrophy. Cornea. 2018 Apr;37(4):523-527. doi: 10.1097/ICO.0000000000001518.</citation>
    <PMID>29384808</PMID>
  </reference>
  <reference>
    <citation>Wacker K, Baratz KH, Bourne WM, Patel SV. Patient-Reported Visual Disability in Fuchs' Endothelial Corneal Dystrophy Measured by the Visual Function and Corneal Health Status Instrument. Ophthalmology. 2018 Dec;125(12):1854-1861. doi: 10.1016/j.ophtha.2018.06.018. Epub 2018 Aug 10.</citation>
    <PMID>30104038</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fuchs' Endothelial Dystrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

